Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Neurology Taiwan

BioDelivery clinches $30M up front from Endo in deal for PhIII buccal mucosa chronic pain treatment

This article was originally published in Scrip

Executive Summary

BioDelivery Sciences International saw its shares surge on news of its partnering deal with Endo Pharmaceuticals on its pain drug BEMA Buprenorphine – a product in Phase III development as potentially the first transmucosal product for the treatment of chronic pain. The product blends the opioid analgesic buprenorphine with BDSI’s BioErodible MucoAdhesive (BEMA) drug delivery technology, whereby a small piece of polymer film is applied to the buccal mucosa (inner lining of the cheek).

Table

View full table

Topics

Related Companies

Tags:
Neurology Taiwan
Latest Headlines

Bolar Exemption India Files: Roche Blocks Alleged Infringer Of Evrysdi Patent

Finance Watch: Investors Support Strategic Shifts At Cullinan, Cidara

Humira Market Erosion Is Continuing As Expected, AbbVie Says

Pfizer Matches Beqvez Price To Hemgenix In Hemophilia B, Plans Warranty Program

See All
UsernamePublicRestriction

Register

SC015816

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By